GPCR.OQ - Structure Therapeutics Inc
Structure Therapeutics Inc
Clear Street LLC

Aleniglipron’s Potential Best-In-Class Profile Shows Up to 16.3% Weight Loss & Positions 180 mg as Leading P3 Dose

公司
GPCR.OQ
日期
2026-03-16
分析师
Ms. Kaveri Pohlman
页数
12
需要登录
请登录后购买研报或生成音频内容。